Assessment of pharmacokinetics and tolerability following single‐dose administration of molnupiravir in participants with hepatic or renal impairment.

Authors: Duncan, Kelly E.¹ (AUTHOR) kelly.duncan1@merck.com, Carstens, Russ P.¹ (AUTHOR), Butterfield, Kristin L.¹ (AUTHOR), Jin, Yoon¹ (AUTHOR), Inbody, Laura R.¹ (AUTHOR), Schaeffer, Andrea K.¹ (AUTHOR), Matthews, Catherine Z.¹ (AUTHOR), Zhao, Tian¹ (AUTHOR), Patel, Shruti¹ (AUTHOR), Maas, Brian M.¹ (AUTHOR), Cheng, Mickie H.¹ (AUTHOR), Stoch, S. Aubrey¹ (AUTHOR), Kraft, Walter¹ (AUTHOR), Sanchez‐Crespo, Nelia¹ (AUTHOR), Rondon, Juan¹ (AUTHOR), Cruz, Kimberly¹ (AUTHOR), Vijil, Julio C.¹ (AUTHOR)

Source: CTS: Clinical & Translational Science. Dec2024, Vol. 17 Issue 12, p1-13. 13p.

Subject Terms: *MOLNUPIRAVIR, *CHRONIC kidney failure, *DISEASE progression, *PHARMACOKINETICS, *INDIVIDUAL needs

Multidrug Combinations against SARS-CoV-2 Using GS-441524 or Ivermectin with Molnupiravir and/or Nirmatrelvir in Reconstituted Human Nasal Airway Epithelia.

Authors: Siegrist, Denise¹ (AUTHOR), Jonsdottir, Hulda R.^1,2,3 (AUTHOR) hulda-run.jonsdottir@babs.admin.ch, Bouveret, Mendy⁴ (AUTHOR), Boda, Bernadett⁴ (AUTHOR), Constant, Samuel⁴ (AUTHOR), Engler, Olivier B.¹ (AUTHOR)

Source: Pharmaceutics. Oct2024, Vol. 16 Issue 10, p1262. 12p.

Subject Terms: *MOLNUPIRAVIR, *COVID-19 treatment, *IVERMECTIN, *SARS-CoV-2, *DRUG development, *ANTIVIRAL agents

Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression.

Authors: Butt, Adeel Ajwad^1,2,3,4 (AUTHOR) aab2005@qatar-med.cornell.edu, Yan, Peng¹ (AUTHOR), Shaikh, Obaid S.^1,5 (AUTHOR)

Source: PLoS ONE. 6/6/2024, Vol. 19 Issue 6, p1-12. 12p.

Subject Terms: *COVID-19, *MOLNUPIRAVIR, *DISEASE progression, *DISEASE risk factors, *THERAPEUTICS

Molnupiravir's real-world effectiveness in COVID-19 outpatients at high risk of severe disease: a single-center study.

Authors: Gmizic, Ivana I.¹ gmizic_ivana@yahoo.com, Barac, Aleksandra^1,2, Todorovic, Nevena¹, Sabanovic, Milos¹, Kekic, Natalija¹, Boskovic, Nikola³, Vujovic, Ankica^1,2, Nikolic, Natasa^1,2, Knezevic, Natasa¹, Milosevic, Ivana^1,2, St, Goran^1,2

Source: Journal of Infection in Developing Countries. May2024, Vol. 18 Issue 5, p694-700. 7p.

Subject Terms: *MOLNUPIRAVIR, *COVID-19, *INTENSIVE care units, *OXYGEN therapy, *COMMUNICABLE diseases

Geographic Terms: BELGRADE (Serbia)

Effect of Nucleic Acid Analog Administration on Fluctuations in the Albumin-to-Globulin Ratio in Cats with Feline Infectious Peritonitis.

Authors: Katayama, Masato¹ (AUTHOR) bloom-animal@blue.plala.or.jp, Uemura, Yukina¹ (AUTHOR), Katori, Daichi² (AUTHOR) daichi.katori@gmail.com

Source: Animals (2076-2615). May2024, Vol. 14 Issue 9, p1322. 14p.

Subject Terms: *PERITONITIS, *MOLNUPIRAVIR, *CAT diseases, *CATS, *DRUG administration

Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID‐19: A systematic review and meta‐analysis.

Authors: Amani, Bahman¹ (AUTHOR), Amani, Behnam¹ (AUTHOR) b_amani@alumnus.tums.ac.ir

Source: Immunity, Inflammation & Disease. Apr2024, Vol. 12 Issue 4, p1-11. 11p.

Subject Terms: *MOLNUPIRAVIR, *CORONAVIRUS disease treatment, *COVID-19, *INTENSIVE care units

Virology and safety profile of Molnupiravir at three different doses for treatment of SARS‐CoV‐2: a systematic review and meta‐analysis.

Authors: Sukaina, Mahnoor¹ (AUTHOR) msukainavazir193@gmail.com, Shuja, Syed Hasan² (AUTHOR), Rehan, Syeda Tayyaba² (AUTHOR), Ochani, Sidhant³ (AUTHOR), Sheryar, Muhammad⁴ (AUTHOR)

Source: APMIS. Mar2024, Vol. 132 Issue 3, p139-151. 13p.

Subject Terms: *MOLNUPIRAVIR, *SARS-CoV-2, *VIRAL genomes, *VIROLOGY, *MEDICAL databases

In Vitro Study of the Cytotoxic and Immunotropic Effects of Molnupiravir and Favipiravir.

Authors: Brodovskaya, E. P.¹ (AUTHOR), Zaslavskaya, K. Ya.¹ (AUTHOR), Ayub, A. M. Al-Haj¹ (AUTHOR), Khutorskaya, I. A.¹ (AUTHOR), Zaborovskii, A. V.² (AUTHOR), Tararina, L. A.² (AUTHOR), Unina, D. V.² (AUTHOR), Sokolov, F. S.² (AUTHOR), Radaeva, O. A.¹ (AUTHOR), Balykova, L. A.¹ (AUTHOR), Pyataev, N. A.¹ (AUTHOR)

Source: Pharmaceutical Chemistry Journal. Feb2024, Vol. 57 Issue 11, p1693-1697. 5p.

Subject Terms: *MOLNUPIRAVIR, *CORONAVIRUS diseases, *ANTIVIRAL agents, *COVID-19, *INTERLEUKIN-1, *CELL survival

Molnupiravir: Mechanism of action, clinical, and translational science.

Authors: Maas, Brian M.¹ (AUTHOR) brian.maas@merck.com, Strizki, Julie¹ (AUTHOR), Miller, Randy R.¹ (AUTHOR), Kumar, Sushma¹ (AUTHOR), Brown, Michelle¹ (AUTHOR), Johnson, Matthew G.¹ (AUTHOR), Cheng, Mickie¹ (AUTHOR), De Anda, Carisa¹ (AUTHOR), Rizk, Matthew L.¹ (AUTHOR), Stone, Julie A.¹ (AUTHOR)

Source: CTS: Clinical & Translational Science. Feb2024, Vol. 17 Issue 2, p1-8. 8p.

Subject Terms: *MOLNUPIRAVIR, *COVID-19, *RNA replicase, *VIRAL load, *VIRAL replication, *VIRAL genomes

N⁴-Hydroxycytidine/molnupiravir inhibits RNA virus-induced encephalitis by producing less fit mutated viruses.

Authors: Ojha, Durbadal¹, Hill, Collin S.², Zhou, Shuntai^2,3, Evans, Alyssa¹, Leung, Jacqueline M.⁴, Schneider, Christine A.¹, Amblard, Franck⁵, Woods, Tyson A.¹, Schinazi, Raymond F.⁵, Baric, Ralph S.^3,6, Peterson, Karin E.¹, petersonka@niaid.nih.gov, Swanstrom, Ronald^2,7, risunc@med.unc.edu

Source: PLoS Pathogens; 9/30/2024, Vol. 20 Issue 9, p1-20, 20p

Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.

Authors: Strizki, Julie M.¹ (AUTHOR) julie.strizki@merck.com, Grobler, Jay A.¹ (AUTHOR), Murgolo, Nicholas¹ (AUTHOR), Fridman, Arthur¹ (AUTHOR), Johnson, Matthew G.¹ (AUTHOR), Du, Jiejun¹ (AUTHOR), Carmelitano, Patricia¹ (AUTHOR), Brown, Michelle L.¹ (AUTHOR), Paschke, Amanda¹ (AUTHOR), De Anda, Carisa¹ (AUTHOR)

Source: Infectious Diseases & Therapy. Dec2023, Vol. 12 Issue 12, p2725-2743. 19p.

Subject Terms: *COVID-19, *MOLNUPIRAVIR, *WHOLE genome sequencing, *COVID-19 treatment, *VIRAL load

Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19.

Authors: Rasmussen, Henrik Berg^1,2 (AUTHOR) henrik.berg.rasmussen@regionh.dk, Hansen, Peter Riis^3,4 (AUTHOR) peter.riis.hansen@regionh.dk

Source: Viruses (1999-4915). Nov2023, Vol. 15 Issue 11, p2151. 18p.

Subject Terms: *MOLNUPIRAVIR, *COMBINATION drug therapy, *PRODRUGS, *ANIMAL models in research, *ORAL drug administration, *INHALATION administration

White targeted chromatographic screening method of Molnupiravir and its metabolite with degradation kinetics characterization and in-silico toxicity.

Authors: Aboras, Sara I.¹ (AUTHOR), Megahed, Ahmed A.² (AUTHOR), El-Yazbi, Fawzy¹ (AUTHOR), Maher, Hadir M.¹ (AUTHOR) hadirrona@yahoo.com

Source: Scientific Reports. 10/20/2023, Vol. 13 Issue 1, p1-21. 21p.

Subject Terms: *MOLNUPIRAVIR, *SARS-CoV-2, *SUNSHINE, *ANTIVIRAL agents, *DRUG approval

Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants.

Authors: Iwamoto, Marian¹ (AUTHOR) marian_iwamoto@merck.com, Duncan, Kelly E.¹ (AUTHOR), Wickremasingha, Prachi K.¹ (AUTHOR), Zhao, Tian¹ (AUTHOR), Liberti, Maria V.¹ (AUTHOR), Lemoine, Lieselotte¹ (AUTHOR), Decaesteker, Tatjana¹ (AUTHOR), Rottey, Sylvie² (AUTHOR), Maas, Brian M.¹ (AUTHOR), Gillespie, Gillian¹ (AUTHOR), Stoch, S. Aubrey¹ (AUTHOR)

Source: CTS: Clinical & Translational Science. Oct2023, Vol. 16 Issue 10, p1947-1956. 10p.

Subject Terms: *MOLNUPIRAVIR, *MONONUCLEAR leukocytes, *PHARMACOKINETICS, *TERMINATION of treatment

Viral target and metabolism‐based rationale for combined use of recently authorized small molecule COVID‐19 medicines: Molnupiravir, nirmatrelvir, and remdesivir.

Authors: Yan, Daisy¹ (AUTHOR), Yan, Bingfang² (AUTHOR) yanbg@uc.edu

Source: Fundamental & Clinical Pharmacology. Aug2023, Vol. 37 Issue 4, p726-738. 13p.

Subject Terms: *MOLNUPIRAVIR, *REMDESIVIR, *SMALL molecules, *ANTIVIRAL agents, *COVID-19

Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters.

Authors: Bakos, Éva¹ (AUTHOR) bakos.eva@ttk.hu, Temesszentandrási-Ambrus, Csilla² (AUTHOR) csilla.temesszentandrasi-ambrus@crl.com, Özvegy-Laczka, Csilla¹ (AUTHOR) laczka.csilla@ttk.hu, Gáborik, Zsuzsanna² (AUTHOR) zsuzsanna.gaborik@crl.com, Sarkadi, Balázs¹ (AUTHOR) sarkadi.balazs@ttk.hu, Telbisz, Ágnes¹ (AUTHOR) telbisz.agnes@ttk.hu

Source: International Journal of Molecular Sciences. Jul2023, Vol. 24 Issue 14, p11237. 12p.

Subject Terms: *COVID-19 treatment, *MOLNUPIRAVIR, *RITONAVIR, *NUCLEOSIDE transport proteins, *COVID-19 pandemic, *COVID-19

Development and Validation of Stability Indicating High Performance Liquid Chromatography Method for Determination of Molnupiravir in Capsule Dosage Form.

Authors: PATEL, R. B.¹ ravipatel.qa@gmail.com, SOLANKI, R. V.¹, CHAUHAN, S. P.¹, PATEL, D. M.¹

Source: Indian Journal of Pharmaceutical Sciences. Jul/Aug2023, Vol. 85 Issue 4, p903-911. 9p.

Subject Terms: *HIGH performance liquid chromatography, *MOLNUPIRAVIR, *SARS-CoV-2, *CLINICAL trials

Geographic Terms: INDIA

Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations.

Authors: Zhou, Shuntai^1,2 (AUTHOR), Long, Nathan¹ (AUTHOR), Rosenke, Kyle³ (AUTHOR), Jarvis, Michael A^3,4,5 (AUTHOR), Feldmann, Heinz³ (AUTHOR), Swanstrom, Ronald^1,6 (AUTHOR)

Source: Journal of Infectious Diseases. 12/15/2024, Vol. 230 Issue 6, p1380-1383. 4p.

Subject Terms: *SARS-CoV-2, *MOLNUPIRAVIR, *MUTAGENESIS, *RITONAVIR, *MACAQUES

Effectiveness and safety of molnupiravir in the intended-use population: an observational cohort study.

Authors: Abu Ahmad, Wiessam^1,2 (AUTHOR), Arbel, Ronen^3,4 (AUTHOR), Wolff Sagy, Yael² (AUTHOR), Battat, Erez² (AUTHOR), Sergienko, Ruslan⁵ (AUTHOR), Friger, Michael⁵ (AUTHOR), Yaron, Shlomit³ (AUTHOR), Serby, Danielle³ (AUTHOR), Zucker, Roy³ (AUTHOR), Hammerman, Ariel³ (AUTHOR), Duskin Bitan, Hadar³ (AUTHOR), Peretz, Alon^3,6 (AUTHOR), Lavie, Gil^2,7 (AUTHOR), Netzer, Doron^3,8 (AUTHOR)

Source: Clinical Microbiology & Infection. Oct2024, Vol. 30 Issue 10, p1305-1311. 7p.

Subject Terms: *COVID-19 treatment, *MOLNUPIRAVIR, *MEDICAL care, *MORTALITY, *COHORT analysis

Molnupiravir Inhibits Porcine Epidemic Diarrhea Virus Infection In Vitro.

Authors: Huang, Zi-Xin^1,2 (AUTHOR), Zhou, Shu-Ting^1,2 (AUTHOR), Yang, Zhi-Biao^1,2 (AUTHOR) zbyang@sjtu.edu.cn, Wang, Zhe^1,2 (AUTHOR) zbyang@sjtu.edu.cn

Source: Viruses (1999-4915). Jun2023, Vol. 15 Issue 6, p1317. 12p.

Subject Terms: *PORCINE epidemic diarrhea virus, *MOLNUPIRAVIR, *VIRUS diseases, *PLANT viruses, *RNA replicase